AN2 Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
ANTX$4.00+1.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $44,318 | $19,941 |
| Short-term investments | 34,069 | 38,060 |
| Prepaid expenses and other current assets | 1,604 | 1,936 |
| Total current assets | 79,991 | 59,937 |
| Long-term investments | 1,469 | 2,013 |
| Other assets, long-term | 216 | — |
| Total assets | $81,676 | $61,950 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,967 | $3,021 |
| Accrued compensation | 1,095 | 2,418 |
| Accrued liabilities | 1,747 | 2,052 |
| Other current liabilities | 776 | 1,229 |
| Total current liabilities | 5,585 | 8,720 |
| Other non-current liabilities | 170 | 170 |
| Total liabilities | 5,755 | 8,890 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025; 36,308,669 and 27,413,171 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 335,107 | 293,953 |
| Accumulated other comprehensive (loss) gain | (23) | 57 |
| Accumulated deficit | (259,163) | (240,950) |
| Total stockholders’ equity | 75,921 | 53,060 |
| Total liabilities and stockholders’ equity | $81,676 | $61,950 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.